参考文献/References:
[1] Russell C,Sheth S,Jacoby D. A clinical guide to combination lipid-lowering therapy[J]. Curr Atheroscler Rep,2018,20(4):19.
[2] Baigent C,Blackwell L,Emberson J,et al. Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomised trials[J]. Lancet,2010,376(9753):1670-1681.
[3] Quispe R,Martin SS,Michos ED,et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB:a primary prevention study[J]. Eur Heart J,2021,42(42):4324-4332.
[4] 刘法,申晓彧. 冠心病与血清残余胆固醇关系的研究进展[J]. 中西医结合心脑血管病杂志,2024,22(10):1817-1819.
[5] Jiang X,Zhuang J,Juan Y,et al. Association between remnant cholesterol and the risk of cardiovascular disease in Chinese population[J]. J Stroke Cerebrovasc Dis,2024,33(8):107825.
[6] Feingold KR. Lipid and lipoprotein metabolism[J]. Endocrinol Metab Clin North Am,2022,51(3):437-458.
[7] Ginsberg HN,Packard CJ,Chapman MJ,et al. Triglyceride-rich lipoproteins and their remnants:metabolic insights,role in atherosclerotic cardiovascular disease,and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society[J]. Eur Heart J,2021,42(47):4791-4806.
[8] Wang K,Wang R,Yang J,et al. Remnant cholesterol and atherosclerotic cardiovascular disease:metabolism,mechanism,evidence,and treatment[J]. Front Cardiovasc Med,2022,9:913869.
[9] Tada H,Nohara A,Inazu A,et al. Remnant lipoproteins and atherosclerotic cardiovascular disease[J]. Clin Chim Acta,2019,490:1-5.
[10] Delialis D,Georgiopoulos G,Aivalioti E,et al. Remnant cholesterol in atherosclerotic cardiovascular disease:a systematic review and meta-analysis[J]. Hellenic J Cardiol ,2023,74:48-57.
[11] Feng Q,Li H,Zhang RY,et al. Elevated remnant cholesterol is a risk factor for acute ischemic stroke[J]. J Stroke Cerebrovasc Dis,2024,33(8):107773.
[12] Luo Y,Cui S,Zhang C,et al. Prognostic role of fasting remnant cholesterol with in-stent restenosis after drug-eluting stent implantation[J]. Int J Gen Med,2022,15:1733-1742.
[13] Chen X,Li LH. Remnant cholesterol,a valuable biomarker for assessing arteriosclerosis and cardiovascular risk:a systematic review[J]. Cureus,2023,15(8):e44202.
[14] Wu Z,Wang J,Zhang H,et al. Longitudinal association of remnant cholesterol with joint arteriosclerosis and atherosclerosis progression beyond LDL cholesterol[J]. BMC Med,2023,21(1):42.
[15] Navarese EP,Vine D,Proctor S,et al. Independent causal effect of remnant cholesterol on atherosclerotic cardiovascular outcomes:a mendelian randomization study[J]. Arterioscler Thromb Vasc Biol,2023,43(9):e373-e380.
[16] Chen MM,Huang X,Xu C,et al. High remnant cholesterol level potentiates the development of hypertension[J]. Front Endocrinol (Lausanne),2022,13:830347.
[17] Guan B,Wang A,Xu H. Causal associations of remnant cholesterol with cardiometabolic diseases and risk factors:a mendelian randomization analysis[J]. Cardiovasc Diabetol,2023,22(1):207.
[18] Sokooti S,Flores-Guerrero JL,Heerspink H,et al. Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes:the PREVEND study[J]. Cardiovasc Diabetol,2021,20(1):156.
[19] Huh JH,Roh E,Lee SJ,et al. Remnant cholesterol is an independent predictor of type 2 diabetes:a nationwide population-based cohort study[J]. Diabetes Care,2023,46(2):305-312.
[20] Ferri N,Corsini A. Clinical pharmacology of statins:an update[J]. Curr Atheroscler Rep,2020,22(7):26.
[21] Miller PE,Martin SS,Joshi PH,et al. Pitavastatin 4 mg provides significantly greater reduction in remnant lipoprotein cholesterol compared with pravastatin 40 mg:results from the short-term phase IV PREVAIL US trial in patients with primary hyperlipidemia or mixed dyslipidemia[J]. Clin Ther,2016,38(3):603-609.
[22] Yoo J,Jeong IK,Ahn KJ,et al. Fenofibrate,a PPARα agonist,reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy[J]. Metabolism,2021,120:154798.
[23] Tsunoda F,Asztalos IB,Horvath KV,et al. Fenofibrate,HDL,and cardiovascular disease in Type-2 diabetes:the DAIS trial[J]. Atherosclerosis,2016,247:35-39.
[24] Das PA,Glynn RJ,Fruchart JC,et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk[J]. N Engl J Med,2022,387(21):1923-1934.
[25] Yanai H,Adachi H,Hakoshima M,et al. Molecular biological and clinical understanding of the statin residual cardiovascular disease risk and peroxisome proliferator-activated receptor alpha agonists and ezetimibe for its treatment[J]. Int J Mol Sci,2022,23(7):3418.
[26] Giugliano RP,Cannon CP,Blazing MA,et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus:results from IMPROVE-IT (improved reduction of outcomes:vytorin efficacy international trial)[J]. Circulation,2018,137(15):1571-1582.
[27] de Filippo O,D’Ascenzo F,Iannaccone M,et al. Safety and efficacy of bempedoic acid:a systematic review and meta-analysis of randomised controlled trials[J]. Cardiovasc Diabetol,2023,22(1):324.
[28] Kosmas CE,Bousvarou MD,Sourlas A,et al. Angiopoietin-like protein 3 (ANGPTL3) inhibitors in the management of refractory hypercholesterolemia[J]. Clin Pharmacol,2022,14:49-59.
[29] Zimerman A,Wiviott SD,Park JG,et al. Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis:an analysis from the TRANSLATE-TIMI 70 trial[J]. Eur J Prev Cardiol,2024,31(10):1216-1223.
[30] Rosenson RS,Gaudet D,Hegele RA,et al. Zodasiran,an RNAi therapeutic targeting ANGPTL3,for mixed hyperlipidemia[J]. N Engl J Med,2024,391(10):913-925.
[31] Taskinen MR,Packard CJ,Boren J. Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD[J]. Curr Atheroscler Rep,2019,21(8):27.
[32] Calcaterra I,Lupoli R,di Minno A,et al. Volanesorsen to treat severe hypertriglyceridaemia:a pooled analysis of randomized controlled trials[J]. Eur J Clin Invest ,2022,52(11):e13841.
[33] Bergmark BA,Marston NA,Prohaska TA,et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk[J]. N Engl J Med,2024,390(19):1770-1780.
[34] Watanabe Y,Tatsuno I. Prevention of cardiovascular events with omega-3 polyunsaturated fatty acids and the mechanism involved[J]. J Atheroscler Thromb,2020,27(3):183-198.
[35] Bhatt DL,Steg PG,Miller M,et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia[J]. N Engl J Med,2019,380(1):11-22.
[36] Siscovick DS,Barringer TA,Fretts AM,et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease:a science advisory from the American Heart Association[J]. Circulation,2017,135(15):e867-e884.
[37] Hess CN,Low WC,Hiatt WR. PCSK9 inhibitors:mechanisms of action,metabolic effects,and clinical outcomes[J]. Annu Rev Med,2018,69:133-145.
[38] Canuel M,Sun X,Asselin MC,et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)[J]. PLoS One,2013,8(5):e64145.
[39] 杨帆,刘楚轩,彭飞,等. PCSK9抑制剂在治疗动脉粥样硬化中的研究进展[J]. 中国动脉硬化杂志,2023,31(3):185-189.
[40] Ragusa R,Basta G,Neglia D,et al. PCSK9 and atherosclerosis:looking beyond LDL regulation[J]. Eur J Clin Invest,2021,51(4):e13459.
[41] Toth PP,Hamon SC,Jones SR,et al. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method:analysis of 3 randomized trials versus placebo[J]. Lipids Health Dis,2016,15:28.
[42] Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[43] Koenig W,Conde LG,Landmesser U,et al. Efficacy and safety of inclisiran in patients with polyvascular disease:pooled,post hoc analysis of the ORION-9,ORION-10,and ORION-11 phase 3 randomized controlled trials[J]. Cardiovasc Drugs Ther,2024,38(3):493-503.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(1):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(1):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(1):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(1):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(1):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(1):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[8]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(1):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[9]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[10]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(1):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
[11]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(1):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[12]杜孝亮 徐静 李樊丹 杨浩 吕湛.残余胆固醇在动脉粥样硬化性心血管疾病中的作用机制研究进展[J].心血管病学进展,2024,(8):732.[doi:10.16806/j.cnki.issn.1004-3934.202.08.013]
DU Xiaoliang,XU Jing,LI Fandan,et al.Action Mechanism of Remnant Cholesterol and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(1):732.[doi:10.16806/j.cnki.issn.1004-3934.202.08.013]